Search results
Results from the WOW.Com Content Network
The hallmark symptom of LATE is a progressive memory loss that predominantly affects short-term and episodic memory. [1] This impairment is often severe enough to interfere with daily functioning and usually remains the chief neurologic deficit, unlike other types of dementia in which non-memory cognitive domains and behavioral changes might be noted earlier or more prominently. [1]
Leukoaraiosis refers to the imaging finding of white matter changes that are common in Binswanger disease. However, leukoaraiosis can be found in many different diseases and even in normal patients, especially in people older than 65 years of age. [5]
Therefore, pneumothorax is usually more of a problem than hemothorax. [8] A pneumothorax may form or be turned into a tension pneumothorax by mechanical ventilation, which may force air out of the tear in the lung. [12] The laceration may also close up by itself, which can cause it to trap blood and potentially form a cyst or hematoma. [8]
Life expectancy of people with AD is reduced. [226] The normal life expectancy for 60 to 70 years old is 23 to 15 years; for 90 years old it is 4.5 years. [227] Following AD diagnosis it ranges from 7 to 10 years for those in their 60s and early 70s (a loss of 13 to 8 years), to only about 3 years or less (a loss of 1.5 years) for those in ...
Pneumothorax is more common in neonates than in any other age group. The incidence of symptomatic neonatal is estimated to be around 1-3 per 1000 live births. Prematurity, low birth weight and asphyxia are the major risk factors, and a majority of newborn infant cases occur during the first 72 hours of life. [26] [27] [14]
Flash pulmonary edema is a clinical syndrome that begins suddenly and accelerates rapidly. Essentially all patients will present to the emergency department by ambulance. The initiating acute event often a vascular event such as intense vasoconstriction and not a cardiac event such as myocardial infarction.
In a double-blind trial of the humanised monoclonal antibody solanezumab (n = 2042), sixteen patients (11 taking the drug, 5 taking a placebo), or 0.78% developed ARIA-E. A further 7 patients developed ARIA-E during an open-label extension of the trial. [4] The effect of ARIA-E depends on the severity and location of the edema.
One group has dementia due to AD, another group has mild memory problems known as mild cognitive impairment (MCI), and the final control group consists of healthy elderly participants. ADNI-1 initially enrolled 200 healthy elderly, 400 participants with MCI, and 200 participants with AD. [6]